Patent intelligence · US
US 8524901
Compositions and methods for inhibition of the JAK pathway
Compositions and methods for inhibition of the JAK pathway
Patent details — US 8524901
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 3, 2013
- Expiration
- Aug 29, 2033
- Applicant
- Rigel Pharmaceuticals, Inc.
- Claims
- 2
- CPC classes
- A61K, A61K31/155, A61K31/506, A61K31/5377
Quick answer
US 8524901 (Compositions and methods for inhibition of the JAK pathway) is held by Rigel Pharmaceuticals, Inc.. Status: granted. Granted Sep 3, 2013. Expires Aug 29, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K31/155, A61K31/506, A61K31/5377, A61K31/538, A61K31/5383
More from Rigel Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384775
Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors
granted -
US 12357623
Method for treating a disease or condition using a pyrazole compound or formulation thereof
granted -
US 12331036
Heterocyclic RIP1 kinase inhibitors
granted -
US 12297202
RIP1K inhibitors
granted -
US 12263180
Method for treatment of COVID-19-associated conditions
granted -
US 12227508
TGF-β inhibitors
granted -
US 12156880
Heterocyclic RIP1 kinase inhibitors
granted -
US 12116354
RIP1 inhibitory compounds and methods for making and using the same
granted
Frequently asked questions
What is US patent 8524901?
US 8524901 (Compositions and methods for inhibition of the JAK pathway) is held by Rigel Pharmaceuticals, Inc.. Status: granted. Granted Sep 3, 2013. Expires Aug 29, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8524901?
Rigel Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 373 pharmaceutical patents for this assignee.
When does US 8524901 expire?
Our index shows an expiration date of Aug 29, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.